These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9608318)

  • 1. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1998 May; 10(3):174-8. PubMed ID: 9608318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Lorenz HM; Kalden JR
    Curr Opin Rheumatol; 1999 May; 11(3):179-84. PubMed ID: 10328576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1997 May; 9(3):206-12. PubMed ID: 9204255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic agents in the therapy of inflammatory rheumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists.
    Kalden JR
    Curr Opin Rheumatol; 1994 May; 6(3):281-6. PubMed ID: 8060762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1995 May; 7(3):191-7. PubMed ID: 7612410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?
    van Royen-Kerkhof A; Vastert BS; Swart JF; Wulffraat NM
    Immunotherapy; 2014; 6(1):1-3. PubMed ID: 24341875
    [No Abstract]   [Full Text] [Related]  

  • 7. New directions for biological therapy in rheumatoid arthritis.
    Elliott MJ; Maini RN
    Int Arch Allergy Immunol; 1994; 104(2):112-25. PubMed ID: 8199454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibody therapy of inflammatory rheumatic diseases.
    Breedveld FC; van der Lubbe PA
    Br Med Bull; 1995 Apr; 51(2):493-502. PubMed ID: 7552078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapeutic approaches in autoimmune rheumatic diseases, with special emphasis on rheumatoid arthritis.
    Kalden JR; Manger B
    Br J Rheumatol; 1995 Mar; 34(3):193-6. PubMed ID: 7728390
    [No Abstract]   [Full Text] [Related]  

  • 10. Biological therapies in rheumatic diseases.
    Conti F; Ceccarelli F; Massaro L; Cipriano E; Di Franco M; Alessandri C; Spinelli FR; Scrivo R
    Clin Ter; 2013; 164(5):e413-28. PubMed ID: 24217844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pathogenesis of rheumatoid arthritis and the development of therapeutic strategies for the clinical investigation of biologics.
    Panayi GS
    Agents Actions Suppl; 1995; 47():1-21. PubMed ID: 7785487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in rheumatic diseases.
    Yuvienco C; Schwartz S
    Med Health R I; 2011 Nov; 94(11):320-4. PubMed ID: 22204094
    [No Abstract]   [Full Text] [Related]  

  • 13. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1996 May; 8(3):195-200. PubMed ID: 8796978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF blockade in rheumatoid arthritis: implications for therapy and pathogenesis.
    Maini RN; Elliott M; Brennan FM; Williams RO; Feldmann M
    APMIS; 1997 Apr; 105(4):257-63. PubMed ID: 9164467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases.
    Botsios C
    Autoimmun Rev; 2005 Mar; 4(3):162-70. PubMed ID: 15823502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble CD4/CD8 molecules in rheumatic disorders.
    Sawada S; Takei M; Mitamura K
    Clin Immunol Immunopathol; 1994 Aug; 72(2):177-80. PubMed ID: 8050190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A brief course of anti-TNF-alpha therapy can cure recurrent episodes of HLA-B27-associated severe and refractory heel enthesitis.
    Olivieri I; Giasi V; Scarano E; Gigliotti P; D'Angelo S; Padula A
    Clin Exp Rheumatol; 2009; 27(6):1057; author reply 1058. PubMed ID: 20149333
    [No Abstract]   [Full Text] [Related]  

  • 18. Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations.
    Sfikakis PP; Tsokos GC
    Clin Exp Rheumatol; 1995; 13(6):763-77. PubMed ID: 8835253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serious infections associated with anticytokine therapies in the rheumatic diseases.
    Giles JT; Bathon JM
    J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
    Furst DE; Breedveld FC; Kalden JR; Smolen JS; Antoni CE; Bijlsma JW; Burmester GR; Cronstein B; Keystone EC; Kavanaugh A; Klareskog L
    Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii2-7. PubMed ID: 12379612
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.